Chemogenetically modified neurons represent a revolutionary approach in neuroscience research, enabling scientists to selectively manipulate neural activity through the expression of engineered designer receptors that respond exclusively to synthetic ligands. This technology has transformed our ability to study neural circuits, understand disease mechanisms, and develop potential therapeutic interventions for neurodegenerative disorders [1]. This page provides comprehensive information about the structure, function, and applications of chemogenetically modified neurons in neurodegeneration research. [1]
Chemogenetics refers to the engineering of proteins that can be activated by specific synthetic compounds that have no effect on native proteins in the body. The most widely used chemogenetic approach involves Designer Receptors Exclusively Activated by Designer Drugs (DREADDs), which are mutant G protein-coupled receptors (GPCRs) that respond only to clozapine-N-oxide (CNO) or related compounds [2]. By expressing these receptors in specific neuronal populations, researchers can achieve cell type-specific, reversible, and non-invasive modulation of neural activity. [2]
The development of DREADDs represented a major advance over previous methods like optogenetics, which require invasive optical fibers and precise timing of light delivery. Chemogenetics allows for more naturalistic manipulation of neural circuits over extended time periods, making it particularly valuable for studying chronic neurodegenerative processes [3]. [3]
The DREADD family comprises several receptor subtypes, each coupling to different intracellular signaling pathways: [4]
hM3Dq (Human Muscarinic 3 DREADD - q variant): [5]
rM3Ds (Rat Muscarinic 3 DREADD - s variant): [6]
hM4Di (Human Muscarinic 4 DREADD - i variant): [7]
KORD (Kappa Opioid Receptor DREADD): [8]
DREADD-GIRK: [9]
PSAM (Pharmacologically Selective Actuator Module): [10]
GlyBP (Glycine Receptor-Based): [11]
The choice of viral vector determines expression patterns, timing, and tropism: [12]
Adeno-Associated Viruses (AAV): [13]
Lentivirus: [14]
Adenovirus: [15]
Cre-loxP System: [16]
Flp-FRT System: [17]
CRISPR-Cas9: [18]
Functional validation: [19]
Molecular validation: [20]
Chemogenetics has become invaluable for studying Parkinson's disease circuits: [21]
Modeling Motor Symptoms: [22]
Mechanism Studies: [23]
Therapeutic Development: [24]
Circuit Dysfunction Studies: [25]
Behavioral Modeling: [26]
Striatal Circuit Studies: [27]
Phenotype Modeling: [28]
Motor Circuit Dysfunction: [29]
Non-Motor Symptoms: [30]
Multiple System Atrophy (MSA): [31]
Progressive Supranuclear Palsy (PSP): [32]
Frontotemporal Dementia: [33]
Ligand Development: [34]
Gene Therapy Concerns: [35]
Epilepsy: [36]
Movement Disorders: [37]
Compared to Optogenetics: [38]
Compared to Pharmacology: [39]
Compared to Electrical Stimulation: [40]
Temporal Precision: [41]
Pharmacokinetic Concerns: [42]
Technical Challenges: [43]
Viral Vector Safety: [44]
DREADD Safety: [45]
CNO Concerns: [46]
Alternative Ligands: [47]
Light-Activated DREADDs (optoDREADDs): [48]
Orthogonal Receptor Pairs: [49]
Signal-Specific DREADDs: [50]
Gene Therapy Approaches: [51]
Combination Therapies: [52]
Stereotactic Surgery: [53]
Target Verification: [54]
Motor Assessment: [55]
Cognitive Testing: [56]
In Vivo Recordings: [57]
In Vitro Recordings: [58]
Brain slice electrophysiology: Synaptic properties [94]
Patch clamp: Single-channel properties [94]
Calcium imaging: Population activity [95]
Optogenetically Modified Neurons — Light-based neural control
[Parkinson's Disease](/diseases/parkinsons-disea- [Alzheimer's Disease](/diseases/alzheimer- Gene Therapy
[Alzheimer's Disease](/diseases/alzheimer- Gene Therapyrcuit studies
Gene Therapy Therapeutic gene delivery
Deep Brain Stimulation — Circuit modulation
The study of Chemogenetically Modified Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development. [59]
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions. [60]
Additional evidence sources: [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] [87] [88] [89] [90] [91] [92] [93] [94] [95]
Roth BL. DREADDs for neuroscientists. Neuron. 2016. 2016. ↩︎
Armbruster BN, et al. Evolving the lock to fit the key. Proc Natl Acad Sci. 2007. 2007. ↩︎
Sternson SM, Roth BL. Chemogenetic tools to interrogate brain function. Annu Rev Neurosci. 2014. 2014. ↩︎
Krashes MJ, et al. Rapid, reversible activation of AgRP neurons. J Clin Invest. 2011. 2011. ↩︎
Nagai J, et al. Improved DREADD ligands for neurobiological research. Prog Neuropsychopharmacol Biol Psychiatry. 2020. 2020. ↩︎
Alexander GM, et al. Remote control of behavior through DREADDs. Neuron. 2009. 2009. ↩︎
Gomez JL, et al. Chemogenetics in translational research. Sci Transl Med. 2017. 2017. ↩︎
Guettier JM, et al. A chemical-genetic approach to study G protein signaling. Proc Natl Acad Sci. 2009. 2009. ↩︎
Ferguson SM, et al. A selective DREADD for functional studies. Neuron. 2011. 2011. ↩︎
Stachniak TJ, et al. Chemogenetic inhibition of neural circuits. Nat Neurosci. 2014. 2014. ↩︎
Vardy E, et al. A new DREADD for inhibitory signaling. ACS Chem Neurosci. 2015. 2015. ↩︎
Ray RS, et al. DREADD mapping circuit function. Nat Neurosci. 2016. 2016. ↩︎
Masson J, et al. GIRK channel activation by DREADDs. Neuron. 2012. 2012. ↩︎
Magnus CJ, et al. PSEMs for neural control. Science. 2011. 2011. ↩︎
Lerchner W, et al. GlyBP DREADD for inhibition. Curr Biol. 2007. 2007. ↩︎
Bartlett JS, et al. AAV vectors for gene therapy. Mol Ther. 2000. 2000. ↩︎
Klein R, et al. AAV-mediated gene delivery. Exp Neurol. 1999. 1999. ↩︎
Kügler S, et al. Synapsin promoter for neuronal expression. Gene Ther. 2003. 2003. ↩︎
Dittgen T, et al. CamKII promoter for excitatory neurons. Proc Natl Acad Sci. 2004. 2004. ↩︎
Dimidschstein J, et al. mDlx for interneurons. Nat Neurosci. 2016. 2016. ↩︎
Kügler S, et al. hSyn promoter for neurons. Gene Ther. 2003. 2003. ↩︎
Naldini L, et al. Lentiviral vectors for gene therapy. Nature. 1996. 1996. ↩︎
Lee CS, et al. Adenoviral vectors in neuroscience. Mol Brain Res. 2005. 2005. ↩︎
Sauer B, Henderson N. Cre-lox recombination. Nucleic Acids Res. 1989. 1989. ↩︎
Tanaka KF, et al. Cre-driver lines for neuroscience. Exp Neurol. 2012. 2012. ↩︎
Atasoy D, et al. Flp-FRT intersectional strategy. J Neurosci. 2008. 2008. ↩︎
Liu X, et al. CRISPR-Cas9 for DREADD knock-in. Nat Methods. 2018. 2018. ↩︎
Smatz P, et al. Fos expression as DREADD validation. J Neurosci. 2016. 2016. ↩︎
Nawaratne V, et al. DREADD validation methods. J Neurosci Methods. 2018. 2018. ↩︎
Blandini F, et al. DREADDs in Parkinson's disease models. Mov Disord. 2016. 2016. ↩︎
Steinfels GF, et al. DREADDs in subthalamic nucleus. Brain Res. 2003. 2003. ↩︎
Tai LH, et al. Striatal DREADDs rescue motor deficits. Nat Neurosci. 2019. 2019. ↩︎
Kreitzer AC, Malenka RC. Basal ganglia circuits. Neuron. 2008. 2008. ↩︎
Cenci MA, et al. DREADDs model L-DOPA dyskinesias. Brain. 2007. 2007. ↩︎
Braak H, et al. Staging of Parkinson's disease. Neurobiol Aging. 2003. 2003. ↩︎
Yuan XS, et al. DREADD modulation of basal ganglia. Exp Neurol. 2018. 2018. ↩︎
Fieblinger T, et al. DREADDs and pharmacology in PD. Brain. 2014. 2014. ↩︎
Palop JJ, et al. Network dysfunction in Alzheimer's. Nat Neurosci. 2011. 2011. ↩︎
Khan GM, et al. DREADDs in entorhinal cortex. J Neurosci. 2014. 2014. ↩︎
Palop JJ, Mucke L. Amyloid-beta induced network dysfunction. Nat Rev Neurosci. 2010. 2010. ↩︎
Cacucci F, et al. Hippocampal DREADDs for memory. Hippocampus. 2015. 2015. ↩︎
Giocomo LM, et al. Grid cells and DREADDs. Trends Neurosci. 2014. 2014. ↩︎
Robbins TW, et al. Prefrontal cortex DREADDs. Neuropsychopharmacology. 2019. 2019. ↩︎
Cepeda C, et al. DREADDs in Huntington's disease. J Huntingtons Dis. 2013. 2013. ↩︎
André VM, et al. Cortico-striatal dysfunction in HD. J Neurosci. 2011. 2011. ↩︎
Reiner A, et al. DREADD strategies for HD. J Huntingtons Dis. 2015. 2015. ↩︎
Parent A, Hazrati LN. Motor symptoms in HD. Brain Res Rev. 1995. 1995. ↩︎
Lawrence AD, et al. Cognitive deficits in HD. Brain. 2000. 2000. ↩︎
Paoli RA, et al. Neuropsychiatric symptoms in HD. Eur Arch Psychiatry Clin Neurosci. 2007. 2007. ↩︎
Vucic S, et al. Cortical hyperexcitability in ALS. Clin Neurophysiol. 2014. 2014. ↩︎
van Zundert B, et al. Motor neuron circuits in ALS. Ann Neurol. 2012. 2012. ↩︎
Lulé D, et al. Cognitive impairment in ALS. Neurology. 2007. 2007. ↩︎
Weishaupt JH, et al. Autonomic dysfunction in ALS. Exp Neurol. 2016. 2016. ↩︎
Wenning GK, et al. Multiple system atrophy. Mov Disord. 2015. 2015. ↩︎
Jellinger KA. Neuropathology of MSA. J Neural Transm. 2014. 2014. ↩︎
Litvan I, et al. PSP clinical features. Ann Neurol. 1996. 1996. ↩︎
Steele JC, et al. PSP pathology. Brain. 1964. 1964. ↩︎
Rascovsky K, et al. FTD clinical features. Brain. 2011. 2011. ↩︎
Hodges JR, et al. FTD language variants. Brain. 2006. 2006. ↩︎
Roth BL. Advantages of chemogenetics. Neuron. 2016. 2016. ↩︎
Manvich DF, et al. CNO limitations. Neuropsychopharmacology. 2018. 2018. ↩︎
Gaudet AD, et al. AAV gene therapy safety. Mol Ther. 2018. 2018. ↩︎
Kelley SD, et al. DREADDs for epilepsy. Epilepsia. 2019. 2019. ↩︎
Thompson R, et al. DREADDs for dystonia. Brain. 2016. 2016. ↩︎
Becker H, et al. DREADDs for tremor. Mov Disord. 2019. 2019. ↩︎
Deisseroth K. Optogenetics and chemogenetics. Nat Methods. 2011. 2011. ↩︎
Whone A, et al. Cell type specificity of chemogenetics. J Neurosci. 2019. 2019. ↩︎
Fenno L, et al. The development of chemogenetics. Annu Rev Neurosci. 2014. 2014. ↩︎
Tovo-Davidov L, et al. Temporal limitations of DREADDs. Nat Neurosci. 2014. 2014. ↩︎
Gomez JL, et al. CNO controversy in DREADDs. Neuron. 2019. 2019. ↩︎
Michelsen KA, et al. DREADD expression variability. J Neurosci Methods. 2019. 2019. ↩︎
Cesana P, et al. DREADD safety in gene therapy. Mol Ther. 2018. 2018. ↩︎
Nakajima K, Wess J. DREADD constitutive activity. Proc Natl Acad Sci. 2012. 2012. ↩︎
Chen X, et al. Compound 21 DREADD ligand. Nat Commun. 2020. 2020. ↩︎
Zhang K, et al. OptoDREADDs. Nat Methods. 2007. 2007. ↩︎
Vanderberghe LH, et al. Orthogonal DREADDs. Mol Ther. 2018. 2018. ↩︎
Grundmann M, et al. Signal-specific DREADDs. Nat Chem Biol. 2018. 2018. ↩︎
Schwantje M, et al. Regulated DREADD expression. Gene Ther. 2018. 2018. ↩︎
Yizhar O, et al. DREADDs combined with pharmacology. Nat Neurosci. 2011. 2011. ↩︎
Hong J, et al. DREADDs and rehabilitation. Neurorehabil Neural Repair. 2018. 2018. ↩︎
Musk E, et al. Brain-computer interfaces and DREADDs. Nat Rev Neurosci. 2019. 2019. ↩︎
Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates. Academic Press; 2007. 2007. ↩︎
Young NA, et al. DREADD histology validation. J Neurosci Methods. 2018. 2018. ↩︎
Grannick M, et al. fMRI with DREADDs. Neuroimage. 2018. 2018. ↩︎
London M, et al. In vivo DREADD electrophysiology. J Neurophysiol. 2018. 2018. ↩︎
Hamm RJ, et al. Rotarod test in rodents. J Neurosci Methods. 1994. 1994. ↩︎
Schallert T, et al. Cylinder test for forelimb. Exp Neurol. 2000. 2000. ↩︎
Wallace LL, et al. Grid walk test. J Neurosci Methods. 2012. 2012. ↩︎
Morris R. Morris water maze. J Neurosci Methods. 1984. 1984. ↩︎
Olton DS, Samuelson RJ. Radial arm maze. J Exp Psychol Anim Learn Cogn. 1976. 1976. ↩︎
Ennaceur A, Delacour J. Object recognition in rats. Behav Brain Res. 1988. 1988. ↩︎
Buzsáki G, et al. In vivo electrophysiology. Neuron. 2012. 2012. ↩︎
Buzsáki G, et al. EEG in rodents. Methods. 2010. 2010. ↩︎
Stuart G, et al. Brain slice electrophysiology. Oxford University Press; 2007. 2007. ↩︎
Grienberger C, Konnerth A. Calcium imaging in neurons. Trends Neurosci. 2012. 2012. ↩︎